


**Help protect  
every way  
you can**



**50%**

At least 50% of sexually active men and women in the U.S. will acquire a genital HPV infection at some point in their lives.

**80%**

At least 80% of sexually active women in the U.S. will have acquired genital HPV infection by 50 years of age.

**99.7%**

Virtually all (99.7%) cases of cervical cancer worldwide are linked to oncogenic types of human papillomavirus (HPV).

**Introducing GARDASIL™ —  
an innovation in the prevention of  
**CERVICAL CANCER**  
CERVICAL DYSPLASIA & GENITAL WARTS**

**95%**

GARDASIL™ demonstrated 95% efficacy against HPV 16/18-related cervical cancer or CIN 2/3, and cervical dysplasia (any grade CIN).

**100%**

GARDASIL™ demonstrated 100% efficacy against HPV 6/11-related external genital warts.

**Vaccinate girls as young as 9 years of age today.**  
GARDASIL™ is indicated for the active immunization of girls, female adolescents, and women 9 through 24 years of age.

  
**GARDASIL™**  
**[Quadrivalent Human Papillomavirus  
(Types 16, 18, 6, 11) Recombinant Vaccine]**